Lucid Capital initiated coverage of Tiziana Life Sciences (TLSA) with a Buy rating and $8 price target Tiziana is developing an intranasal antibody for numerous central nervous system conditions, the analyst tells investors in a research note. The firm believes the company is building a neurological franchise with foralumab that could be analogous to AbbVie’s Humira.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TLSA:
- Tiziana Life Sciences Unveils Promising Alzheimer’s Treatment Findings
- Tiziana Life announces immunologic analysis of nasal foralumab in AD patients
- Tiziana Life Sciences Expands Phase 2 MS Trial with New Site
- Tiziana Life Sciences expands Phase 2 intranasal foralumab trial with dosing
- Tiziana Life Sciences to Present Intranasal Foralumab Findings at Bio International Convention